

⑨



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑩

Publication number:

**0 283 606  
A1**

⑪

# **EUROPEAN PATENT APPLICATION**

⑫

Application number: 87302547.2

⑬

Int. Cl. 4: **G01N 33/68**, G01N 33/60,  
G01N 33/543

⑭

Date of filing: 24.03.87

⑮

Date of publication of application:  
28.09.88 Bulletin 88/39

⑯

Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI NL SE

⑰

Applicant: **Technion Research & Development  
Foundation Ltd.**  
Technion City  
Haifa(IL)

Applicant: **Silberman, Michael**  
45 Yotam Str.  
IL-Haifa(IL)

⑱

Inventor: **Silberman, Michael**  
45 Yotam Street  
IL-Haifa(IL)

⑲

Representative: **Clifford, Frederick Alan et al**  
**MARKS & CLERK** 57/60 Lincoln's Inn Fields  
London WC2A 3LS(GB)

⑳

**Method for the detection of pregnancy disorders.**

㉑

The present invention relates to a method for determining pregnancy disorders by analysing a biological fluid sample. According to the method, an antigen consisting of a specific non-hormonal human-derived placental soluble protein is labelled by a radioactive iodine. The sample and a first antibody compatible with the placental antigen is incubated and to the product obtained is applied a second antibody attached to a solid composition. In the resulted precipitated complex the radioactivity is determined thus establishing the extent of pregnancy disorders. The best results are obtained when the protein to be labelled is present at a concentration of above 0.7 mg/ml. A preferred non-hormonal human-derived placental soluble protein is PP-13. The biological fluid sample is selected from blood, amniotic fluid or urine.

**BEST AVAILABLE COPY**

**EP 0 283 606 A1**

The present invention relates to a new method for the detection of pregnancy disorders. More particularly, the invention relates to a new method for detection of placental damages at a relatively early stage of pregnancy.

5

## **BACKGROUND OF THE INVENTION**

As known, high risk pregnancies constitute about 10 to 25% of pregnancies. Among the high risk pregnancies disorders the following can be mentioned: diabetes, kidney diseases (such as chronic pyelonephritis, chronic glomerulonephritis and renal insufficiency), heart disease (such as primary pulmonary) hypertension. The known methods for controlling the pregnancy progress, have the disadvantage that they detect the status of pregnancy disorders at a stage when the clinical signs and symptoms are already apparent.

There are several hormone assays suggested to give an indication whether placental function is normal or to predict impending fetal death. The tests most widely used are: urine estriol, urine total estrogens, serum unconjugated estriol and serum placental lactogen. As known, estriol is an estrogenic compound produced by the placenta from precursors derived from fetal adrenal cortex and fetal liver. The conjugated form of estriol is excreted in maternal urine. Serum estriol can be measured either as total estriol or as unconjugated estriol. It usually is measured as unconjugated estriol in order to exclude maternal contribution to the conjugated fraction. Urine estriol can be measured as total estriol or as total estrogens, since estriol normally constitutes about 90% of urine total estrogens.

Estriol can be detected by immunoassay as early as the ninth week of gestation. Thereafter, estriol values slowly but steadily increase until the last trimester, when there is a more pronounced increase. Clinical use of estriol measurement is based on the fact that severe acute abnormality of the fetoplacental unit, such as a dead or dying placenta, is manifested either by failure of the estriol level to continue rising or by a sudden marked and sustained decrease in the estriol level. A very recent report (M. Scharf et.al. J.Obstet. Gynec.reprod. Biol., 17 365-75, 1984) concludes that in view of the low correlation between patients with abnormal serum free estriol as the antepartum pathological test, the estriol measurement can not be considered a reliable predicting tool to estimate the actual postpartum state in the pregnancy disorders.

Urine total estrogen was the first test used, since total estrogen can be assayed by standard clinical techniques. However, urine glucose, falsely increases the results and certain other substances such as urobilinogen also may interfere. On the other hand, maternal hypertension, preeclampsia, severe anemia and impaired renal function can decrease urine estrogen or estril secretion considerably. Decrease in the contents may also occur to variable degree in a number of fetuses with severe congenital anomalies. It was also reported that continued bed-rest to the pregnant woman, caused an increase in the estriol excretion values of about 20 to 30% over the levels determined from ambulatory persons.

Because of the problems associated with collection of urine or serum estriol specimens and interpretation of the values, as well as the disturbing number of false positive and negative test results, most of the clinical people refrain from correlating these measurements with placental damages. Moreover, all the previous methods did not reveal the pregnancy disorders at an early stage of their appearance, but only when the particular disease was already existent.

## **SUMMARY OF THE INVENTION**

It is an object of the present invention to provide a simple method for the detection of pregnancy disorders at an early stage of their appearance. It is another object of the present invention, to provide a simple method for the detection of pregnancy disorders, said method being of a high sensitivity. It is yet another object of the present invention to provide a simple method for the detection of pregnancy disorders, said method being not influenced by other extraneous factor related thereto. The invention is based on the approach by which antigenic compounds are released from a pathological involved tissue into body fluids, using a particular protein specific to human placenta, and can be subsequently determined. Thus the invention consists of a method for determining pregnancy disorders by analysing a biological fluid sample, which comprises the steps of:

(a) labelling by radioactive iodine an antigen consisting of a non-hormonal human-derived placental soluble protein characterized by the following physico-chemical properties: (1) electrophoretic mobility, in the range specific for albumen; (2) isoelectric point, in the range of between 4.6 to 4.9; (3) molecular weight, below 35,000 Daltons; and (4) carbohydrate content, below 1%;

(b) incubating said biological fluid sample with the labelled antigen and a first antibody, compatible with the placental antigen;

(c) applying to the product obtained in step (b) a second antibody attached to a solid composition, precipitating a complex; and

(d) determining the radioactivity in said complex, thus establishing the extent of pregnancy disorders.

It was surprisingly found that using the above procedure with the particular protein, it is possible to establish an early detection of placental damage in pregnant woman. This is in contrast to known prior tests which are claiming to determine the pregnancy disorders only after their existence in an advanced stage of placenta illness.

A soluble protein possessing the above physico-chemical properties, found to be suitable for the present invention, was discovered in the last few years and names PP13. This protein is described in the European Patent Application Number 101.603 (assigned to Behringwerke Aktiengesellschaft). As mentioned in the patent specification, this protein could be useful for the diagnostic purpose of tumors detection of trophoblastic character.

The discovery according to the present invention, to utilize a placental protein for the prediction of occurrence of pregnancy disorders is quite surprising, in view of prior art statements which discuss various placental proteins, stipulating that they are of no value for this purpose (British Journal of Obstetrics and Gynaecology, December 1984, Vol. 91, page 1224). The inventor carried out a number of experiments with various placental proteins which do not possess all the above four physico-chemical properties and found indeed that there are many placental proteins which are indeed not suitable for the present invention although they possess one or two of the above properties. Thus for instance PP-4 has a molecular weight of 35,000 (i.e. as required by the present invention) but its carbohydrate content is 2.4% compared with below 1% required by the present invention and accordingly was found to be unsuitable.

Another placental protein, named PP-9 was described and characterized by H.Bohn et al (New soluble placental tissue proteins: Immunology of Human Placental Proteins, Placental Supplement 4, 1982 Praeger Publishers). Its isoelectric point is given to be between 6.4-6.7 and carbohydrate content 5.5%, which are not according to the present invention. The inventor has found that PP-9 is not suitable for the method being of no value in the prediction of occurrence of pregnancy disorders.

The inventor is not yet in a position to explain the theoretical aspects, why only a placental protein possessing all the above four physico-chemical properties, such as PP-13, is suitable for the present method, while other placental proteins are unsuitable. However such theoretical explanations are beyond the scope of the invention.

Among the biological fluid to be analyzed, for the antigen determination according to the present invention, the following shall be mentioned: blood, amniotic fluid or urine.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 presents the graphs correlating the percentage of specific binding versus the concentration of the PP-13 protein,

Figure 2 presents the correlating graph of the  $^{125}\text{I}$  radioactivity versus the PP-13 protein concentration,

Figure 3 presents the cumulative distribution in the sera for four groups of population samples.

#### **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The first step of labelling the protein by radioactive iodine, is known in the art by the term radioimmunoassay. As known, the radioimmunoassay is based on the competition of a known excess amount of radiolabelled antigen and an unknown variable amount of the unlabelled antigen, for binding sites of a constant amount of antibody. The specific particular method selected for labelling the antigen, is the so called solid phase antibody. This labelling was carried out according to the method of Marchalonis (Biochemical Journal, Volume 113, 1963) with Lactoperoxidase- $\text{H}_2\text{O}_2$ . Due to the alkalinity of the mixture, some phosphate buffer saline, was also added so that the mixture reached a neutral point. The use of

radioactive isotopes has enabled the immune reaction to be more easily observed and thus it is preferably to be utilized in the present invention, wherein the specific protein can be determined with great sensitivity.

The radioactive iodine bounded by the antigen is counted, using a Gamma Counter (such as Auto Gamma produced by Packard) and the yield thereto is calculated. The yield is calculated using the following formula:

$$\text{Yield} = \frac{\text{radioactivity measured by the peak of protein}}{\text{Total radioactivity}} \times 100$$

The most preferred concentrations of the antibody for obtaining the proper complex (AG - AB) is between 1 10,000 to 1-50,000. In this range it was discovered that there is a linear correlation between the specific binding and antibody concentration. This appears in a clear manner in Figure 1, wherein the specific binding (expressed in percentage) is given versus the concentration of the PP-13 protein. Based on the yield of the radioactive iodine, the specific activity of the labelled antigen is calculated and subsequently this is correlated with standard evaluation curves.

In the second step, the labelled antigen obtained in step (a) is correlated with the biological fluid (blood, amniotic fluid or urine) and a first antibody. This antibody was obtained from antiserum of the placental antigen in a rabbit, diluted by a buffer (pH = 7.4) consisting of NaN<sub>3</sub> (1 g/l) and TRIS - HCl (0.02 mol/l).

In the third step, a second antibody, attached to a solid support, developed in the serum of a donkey, was admixed with the product of step (b) and the precipitated complex was separated by centrifugation and washed with a Phosphate Buffer Saline solution.

Finally, in the fourth step, the radioactivity was determined in the washed complex by an Auto Gamma (produced by Packard).

The above steps of the method will enable to obtain the following data:

- (1) The degree level of total radioactivity introduced in the system of the experiment;
- (2) The degree of non-specific binding of the labelled antigen and the second antibody;
- (3) The zero binding of the antigen and its specific antibody;
- (4) Calibration of the system by utilizing a series of known concentrations of the unlabelled antigen. In the attached Figure 2, it is presented the radioimmunoassay calibration curve of the protein, correlating the <sup>125</sup>I radioactivity (expressed in counts per minute) versus the PP-13 protein concentration (expressed in ng/ml).

The method according to the present invention was applied to four groups of population samples: (1) adults males; (2) adults non-pregnant females; (3) adult asymptomatic pregnant females; and (4) adult symptomatic pregnant females. The same procedure, with exactly the same reagents and amounts thereof, was employed for all four groups and the results obtained are illustrated in the attached Figure 3. In this Figure, there are correlated the cumulative distribution in the sera for the above four groups versus the concentration of the PP-13 protein. From the graphs presented therein it can be noticed that the group of pregnant females differ from the group of males as well as the group of non-pregnant females. It can be also noticed that, there is a substantially equal concentration of protein for the adult males and non-pregnant females at the same cumulative distribution. However, there is a sharp difference in the protein concentration between asymptomatic pregnant females and symptomatic pregnant females, this concentration being substantially higher in the latter group than in the former group particularly at a cumulative distribution of above 0.4, the gap being particularly sensible when the protein concentration is above 0.7 ng/ml. The interpretation method is according to Siegel S (Non-parametric statistics for the behavioural Sciences, Mc.Graw-Hill, 1956, New York).

In the following Table 1 are presented some statistical values concerning the distributional pattern of the PP-13 protein taken as antigen, determined with the method according to the present invention, for the above four groups of population samples. The protein concentration in the blood samples tested was in the range of 0.3 - 2.4 ng/ml.

**TABLE 1.**

**Statistics of the distribution of the PP-13 protein tested**  
**in sera of males, nonpregnant females, healthy pregnant**  
**females and nonhealthy pregnant females.**

	Males	Nonpregnant	<u>Pregnant females</u>	
			Healthy	Nonhealthy
Number	18	48	92	150
Mean (ng/ml)	0.58	0.61	0.82	0.95
Standard deviation	0.14	0.20	0.16	0.34
1st Quartile	0.46	0.48	0.71	0.71
2nd Quartile	0.58	0.56	0.82	0.90
3rd Quartile	0.67	0.68	0.90	1.15

From the results presented in the above Table 1, it can be noticed that the protein level is substantially the same in the blood samples of males and non-pregnant females. The level of protein appears to be higher in pregnant females, where in about 75% of the pregnant females there is a protein level of above 0.71 ng/ml. This difference which appears in the Table is significant, from a statistical point of view ( $P = 0.0035$ ) using the Mann-Whitney criterium. It can also be noticed that in about 50% of nonhealthy pregnant females (compared with about 25% of healthy pregnant females) the value of protein is higher than 0.9 ng/ml.

According to another embodiment of the present invention, the placental protein possessing the above mentioned four physicochemical properties, such as PP-13 can be utilized not only for diagnostic but also for monitoring the pregnancy development and occurrency of placental damage. The method can reveal any abnormal development due to medical treatment for a pregnant female such as diabetes, anemia, hypertension, renal, thyroid etc. Based on the results, the physician will decide whether the pregnancy should be ceased, or to change the dose of the medicine, or even to change completely the medicine taken by the pregnant female.

Thus the pregnancy monitoring by the method according to the present invention will be of high importance, being most appreciated by a person versed in the art. This is a most surprising finding, in view of prior statements which conclude that placental proteins could not be specific to pregnancy in view of the differences which exist between them.

While the invention will be hereafter described in a detailed manner with certain preferred embodiments and compositions, it will be understood that it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover other alternatives, modifications or other ingredients as may be included within the scope of the invention as defined by the appended Claims. It should be understood that the particulars are by way of example and for purposes of illustrative discussion of the procedure for carrying out the method according to the present invention, without being limited thereto.

The reagents utilized in the following Examples and the source are as follows:

- Protein PP-13, produced by Behringwerke Aktiengesellschaft, Lot No. 211/233.
  - Anti PP-13, antiserum, Lot No. 160 Z B.
  - Radioactive iodine ( $^{125}\text{I}$ ) produced by Israel Nuclear Center in a solution of Sodium hydroxide ( $\text{pH} = 8-11$ ) possessing a specific activity of 15-20  $\mu\text{Ci}/\mu\text{g}$ .
  - Lactoperoxidase, produced by Sigma (St. Louis, Missouri) Lot No. 2005.
  - Hydrogen Peroxide, 30% concentration, produced by Sigma, Lot No. H-1009.
- The instruments utilized for the measurements were as follows:
- Gamma Counter, produced by Elscint, Israel (Integrated Nuclear Spectrometer, model INS-11N).

- Auto Gamma 400 (GD, produced by Packard (U.S.A.).
- Cooled Ultra Centrifuge, produced by Cryofuge, Heraeus, West-Germany.
- Column Sephadex G-100 (9 x 550 mm).
- Fraction Collector, produced by Pharmacia, Frac-100 (Sweden).

5

### Step a

The labelling was done by radioactive iodine ( $^{125}\text{I}$ ), at room temperature in a 2 ml plastic test tube, having at its bottom a metal rod operated by a magnetic stirrer, which rotates at 2 rotations per seconds. The following reagents were introduced:

- 3  $\mu\text{g}$  of placental protein in 10  $\mu\text{l}$  of phosphate buffer saline (pH = 7.2);
- 1  $\mu\text{g}$  of lactoperoxidase in 6  $\mu\text{l}$  of phosphate buffer saline;
- 325-350  $\mu\text{Ci}$  of  $^{125}\text{I}$  in 2  $\mu\text{l}$  of NaOH (pH = 8-11); and
- 9 nmole of hydrogen peroxide in 10  $\mu\text{l}$  of phosphate buffer saline.

The reaction solution consisted of 5  $\mu\text{g}$  of PP-13 to which it was added 1  $\mu\text{g}$  of lactoperoxidase and 325  $\mu\text{Ci}$  of  $^{125}\text{I}$ . Due to the relative high alkalinity prevailing thereto, an amount of 3  $\mu\text{l}$  of phosphate buffer solution (0.4 M) was added the pH reaching a neutral value. The iodination reaction started by the addition of hydrogen peroxide and continued for about 3 minutes. The iodination was stopped by adding 300  $\mu\text{l}$  of a solution consisting of: phosphate buffer saline containing 10 g/l of bovine serum albumen; NaI (2 g/l);  $\text{NaN}_3$  (1 g/l) and NaCl (8.5 g/l). After an additional stirring for 1 minute, the mixture was passed over a Sephadex G-100 column for extracting out the labelled protein from the free iodine and the other reagents, by a solution consisting of: phosphate buffer saline + 1% bovine serum albumen and 0.1%  $\text{NaN}_3$ . From the resulted fractions the extent of iodination was determined by a Gamma Counter (Elsint) and the calculated yield was found to be 64.6%.

In order to calculate the specific activity of the labelled antigen, samples of 10  $\mu\text{l}$  were taken and again counted by Packard Gamma Counter and found to be 86178 cpm/ng.

### Step b.

Standard solutions of various concentrations in the range of 0.2 ng/ml to 64 ng/ml of antigen in a buffer (tris HCl, pH = 7.4, 0.02 M and  $\text{NaN}_3$ , 1 g/l) were prepared.

The labelled antigen consisted of a diluted solution of 1 ng/ml. The first antibody, was the antiserum of the placental antigen diluted in a buffer (with the same composition as above).

40

45

50

55

### Step c.

The second antibody, was developed in the serum of a donkey. The test was carried out in a plastic test tube, the working scheme being described in the following Table 2.

**TABLE 2.**

The working scheme for the determination of placental antigen in the human serum using radioimmunoassay.

Kind of incubate	Buffer A: Tris-HCl, pH=7.4(0.02m/l)+ NaN (1 g/l) 3 ( $\mu$ l)	Standards ( $\mu$ l)	Sample ( $\mu$ l)	Tracer ( $\mu$ l)	First antigen antibody ( $\mu$ l)	Second antibody ( $\mu$ l)
Total Radioactivity	200	-	-	100	-	-
Nonspecific binding	200	-	-	100	-	500
Zero binding	100	-	-	100	100	500
Standards	-	100	-	100	100	500
Samples	-	-	100	100	100	500

The reactions between the labelled antigen with the sample of serum or respective standards were carried out for about 18 hours are followed by the addition of the second antibody and agitated for about 10 minutes. The mixtures were centrifuged at room temperature for 30 minutes (at 1000 x C) and the precipitates washed with 500  $\mu$ l of phosphate buffer saline and again centrifuged.

The radioactivity in the washed precipitate was determined by Packard Gamma Counter. The results obtained are summarized in the attached Figure 1. It clearly appears from said Figure that an antibody (A b) with a concentration of 1/50000, gave an adequate binding range for an antigen concentration of between 0.4-32 ng/ml.

In order to calculate the antigen concentrations in the samples tested, a calibration curve was prepared (shown in Figure 2) correlating the radioactivity of  $^{125}$ I (expressed in counts per minute) versus the PP-13 concentration (expressed in ng/ml).

The results obtained according to the method described in this Example, which were obtained on four groups of population samples: adults males, adults non-pregnant females, adult asymptomatic pregnant females and adult symptomatic pregnant females are illustrated in a graphic manner in Figure 3.

### EXAMPLE 2

Using the same reagents, procedures and working scheme as described in Steps a,b,c and Table 2, seven samples of clear amniotic fluid were analyzed.

The results of these determinations are summarized in Table 3.

Table 3Concentration of PP-13 in Human Amniotic Fluid

5	Sample No.	Concentration of PP-13 (ng/ml)
	1	1.24
10	2	2.99
	3	3.66
15	4	2.07
	5	3.13
	6	1.57
20	7	2.86

25 Based on the above results, graphs were drawn correlating the concentration of the PP-13 versus the specific binding (expressed in percentage) and the  $^{125}\text{I}$  radioactivity (expressed in counts per minute). These graphs were identical as those obtained with serum as illustrated in Figures 1 and 2 based on Example 1, where human serum was analyzed.

30

**Claims**

1. A method for determining pregnancy disorders by analysing a biological fluid sample, which comprises the steps of:

35 (a) labelling by radioactive iodine an antigen consisting of a non-hormonal human-derived placental soluble protein, characterized by the following physico-chemical properties:

- electrophoretic mobility, in the range specific to albumen;
- isoelectric point, in the range of between 4.6 to 4.9;
- 40 - molecular weight, below 35,000 Daltons; and
- carbohydrate content, below 1%;

(b) incubating said biological fluid sample with the labelled antigen and a first antibody, compatible with the placental antigen;

(c) applying to the product obtained in step (b) a second antibody attached to a solid composition, precipitating a complex; and

45 (d) determining the radioactivity in said complex, thus establishing the extent of pregnancy disorders.

2. A method according to Claim 1, wherein said biological fluid is selected from the group consisting of blood, amniotic fluid and urine.

3. A method according to Claim 1, wherein said hormonal human -derived placental soluble protein is PP-13.

50 4. A method according to Claims 1 to 3, wherein the level of said protein is above 0.71 mg/ml.

5. A method according to Claim 1, wherein the labelling of the protein involves the following steps:

- (a) extracting the labelled antigen using a solid adsorbent;
- (b) counting the radioactive iodine bounded specifically by the antigen and the yield thereto;
- 55 (c) calculating the specific activity of the labelled antigen; and
- (d) correlating said specific activity with standard evaluation curves.

6. A method according to Claim 1, wherein the first antibody is obtained from antiserum of the placental antigen in an animal.



7. A method according to Claim 6, wherein said antiserum is diluted by a buffer at a pH of about 7.4.
8. A method according to Claim 7, wherein said buffer consists of NaN<sub>3</sub> and TRIS-HCl.
9. A method according to Claims 6 to 8, wherein the concentration of the first antibody, for obtaining the proper complex AG-AB, is between 1:10,000 to 1:50,000.
- 5 10. A method according to Claim 1, wherein the radioactivity of the labelled antigen was counted by Auto Gamma.
11. A method for determining pregnancy disorders by analysing a biological fluid sample, substantially as described in the specification and claimed in any of the previous Claims.

10

15

20

25

30

35

40

45

50

55





FIG.1.

Reçu  
Nouvellement déposé

0 265 000

# PP<sub>13</sub>, RIA CALIBRATION CURVE



PP<sub>13</sub> Concentration (ng/ml)

FIG. 2.

# CUMULATIVE DISTRIBUTION OF PP<sub>13</sub> IN SERA OF:




FIG.3. Concentration Of PP<sub>13</sub>(ng/ml)



EP 87 30 2547

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
Y,D	EP-A-0 101 603 (BEHRINGWERKE AG) * Whole document *	1-4, 6, 11	G 01 N 33/68 G 01 N 33/60 G 01 N 33/543
Y	--- CHEMICAL ABSTRACTS, vol. 104, no. 19, 12th May 1986, page 461, abstract no. 166150q, Columbus, Ohio, US; G. THAN et al.: "Placental protein (PP5, PP10, PP12, PP13, PP17) levels in sera and in amniotic fluid during healthy pregnancy", & MAGY. NOORV. LAPJA 1986, 49(1), 11-15 * Whole abstract *	1-4, 6, 11	
Y	--- L.A. HANSON et al.: "Immunology", 1985, pages 47-48, Butterworth & Co. Ltd; * Page 47, line 35 - page 48, line 5 *	1-4, 6, 11	TECHNICAL FIELDS SEARCHED (Int. Cl.4)
A	--- CHEMICAL ABSTRACTS, vol. 99, no. 7, 15th August 1983, page 316, abstract no. 50851t, Columbus, Ohio, US; H. BOHN et al.: "Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17)", & ONCODEV. BIOL. MED. 1983, 4(5), 343-50 * Whole abstract *	1-4	G 01 N
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12-11-1987	Examiner HITCHEN C.E.
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	CHEMICAL ABSTRACTS, vol. 95, no. 3, 20th July 1981, page 480, abstract no. 22529t, Columbus, Ohio, US; H.T. SALEM et al.: "Measurement of placental protein 5, placental lactogen and pregnancy-specific betal glycoprotein in mid-trimester as a predictor of outcome of pregnancy", & BR. J. OBSTET. GYNAECOL. 1981, 88(4), 371-4 * Whole abstract *	1,2,11	
A	--- EP-A-0 060 491 (BEHRINGWERKE AG) * Page 1, lines 1-22; page 6, line 18 - page 8, line 10; claims 1,3 *	1,2,6	
A	--- EP-A-0 141 326 (BEHRINGWERKE AG) * Page 1, lines 1-11; page 8, line 27 - page 10, line 35; claims 1,3 *	1,2,6-8	
-----			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12-11-1987	Examiner HITCHEN C.E.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**